TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05303701: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Administration of GV1001 1.12 mg/Day in Patients Wi

Sponsor: Samsung Pharmaceutical Co., Ltd. · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 750 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$17,630,720

Rescue Site Savings

+$11,625,256

Unlock Full NCT05303701 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05303701 Rescue Dossier →